Ubs Oconnor LLC Bicycle Therapeutics PLC Transaction History
Ubs Oconnor LLC
- $1.44 Billion
- Q1 2025
A detailed history of Ubs Oconnor LLC transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Ubs Oconnor LLC holds 148,722 shares of BCYC stock, worth $1.22 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
148,722Holding current value
$1.22 Million% of portfolio
0.09%Shares
12 transactions
Others Institutions Holding BCYC
# of Institutions
101Shares Held
42.8MCall Options Held
15.6KPut Options Held
27.7K-
Baker Bros. Advisors LP New York, NY10.9MShares$89.3 Million1.1% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$30.3 Million0.08% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$28.3 Million7.08% of portfolio
-
Armistice Capital, LLC New York, NY2.67MShares$21.9 Million0.35% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$21.8 Million0.12% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $243M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...